Investor Overview


About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Recent News

Natera Reports Fourth Quarter and Year 2019 Financial Results  -  2/26/2020
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an update on recent More »
Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call  -  2/19/2020
SAN CARLOS, Calif. , Feb. 19, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019 , after the market close on February 26, 2020 . More »
Natera Files False Advertising Counterclaim Against CareDx  -  2/18/2020
CareDx's advertising obfuscates AlloSure's poor performance SAN CARLOS, Calif. , Feb. 18, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it has filed suit against CareDx for false advertising in the U.S. More »
Natera Files Suit Against ArcherDX for Patent Infringement  -  1/27/2020
SAN CARLOS, Calif. , Jan. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent"). The complaint was filed in the U.S. District Court of Delaware . More »
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer  -  1/15/2020
Pivotal Study of 1500 Patients Could Lead to Change in Practice Guidelines SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective, More »

Upcoming Events


Past events

Wednesday, 01/15/20 at 10:00 AM PST

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.